Endothelial vascular toxicity from chemotherapeutic agents: Preclinical evidence and clinical implications

Cancer Treatment Reviews

Volumn 38, Issue 5, 2012, Pages 473-483

  Soultati, Aspasia ^a   Mountzios, Giannis ^a   Avgerinou, Chrysoula ^b   Papaxoinis, George ^b   Pectasides, Dimitrios ^b   Dimopoulos, Meletios Athanassios ^b   Papadimitriou, Christos ^b  

^a 251 GENERAL AIR FORCE HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Antimetabolites; Cytotoxics; Endothelium; Flow mediated dilatation; Nitrate mediated dilatation; Platinum compounds; Taxanes; Toxicity; Vascular endothelial growth factor; Vinca alkaloids

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; VINBLASTINE; VINCA ALKALOID;

CELL MIGRATION; CELL PROLIFERATION; DRUG CYTOTOXICITY; DRUG MECHANISM; ENDOTHELIAL VASCULAR TOXICITY; ENDOTHELIUM CELL; HUMAN; NONHUMAN; OXIDATIVE STRESS; REVIEW;

ANGIOGENESIS INHIBITORS; ANTHRACYCLINES; ANTIMETABOLITES; ANTINEOPLASTIC AGENTS; BLEOMYCIN; CYCLOPHOSPHAMIDE; ENDOTHELIUM, VASCULAR; HUMANS; METHOTREXATE; PLATINUM COMPOUNDS; TAXOIDS; VINCA ALKALOIDS;

EID: 84861186078     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.09.002     Document Type: Review

References (167)

1. Pries A.R., Kuebler W.M. Normal endothelium. Handb Exp Pharmacol 2006, (176 Pt 1):1-40.
2. Doll J.A., Reiher F.K., Crawford S.E., Pins M.R., Campbell S.C., Bouck N.P. Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate 2001, 49:293-305.
3. Maeshima Y., Sudhakar A., Lively J.C., et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002, 295:140-143.
4. Guo Y.L., Wang S., Colman R.W. Kininostatin, an angiogenic inhibitor, inhibits proliferation and induces apoptosis of human endothelial cells. Arterioscler Thromb Vasc Biol 2001, 21:1427-1433.
5. Reinmuth N., Stoeltzing O., Liu W., et al. Endothelial survival factors as targets for antineoplastic therapy. Cancer J 2001, 7(Suppl. 3):S109-S119.
6. Lennernas B., Albertsson P., Lennernas H., Norrby K. Chemotherapy and anti-angiogenesis: drug-specific, dose related effects. Acta Oncol 2003, 42:294-303.
7. Kerbel R.S., Viloria-Petit A., Klement G., Rak J. 'Accidental' anti-angiogenic drugs: anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 2000, 36:1248-1257.
8. Miller K.D., Sweeney C.J., Sledge G.W. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001, 19:1195-1206.
9. Belotti D., Vergani V., Drudis T., et al. The microtubule affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996, 2:1843-1849.
10. Vacca A., Iurlaro M., Ribatti D., et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 1999, 94:4143-4155.
11. Clements M.K., Jones C.B., Cumming M., Daoud S.S. Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother Pharmacol 1999, 44:411-416.
12. Doll D.C., Yarbro J.W. Vascular toxicity associated with antineoplastic agents. Semin Oncol 1992, 19:580-596.
13. Licciardello J.T., Moake J.L., Rudy C.K., Karp D.D., Hong W.K. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology 1985, 42:296-300.
14. Hansen S.W., Olsen N., Rossing N., Rorth M. Vascular toxicity and the mechanism underlying Raynaud's phenomenon in patients treated with cisplatin, vinblastine and bleomycin. Ann Oncol 1990, 1:289-292.
15. Roca E., Bruera E., Politi P.M., et al. Vinca alkaloid-induced cardiovascular autonomic neuropathy. Cancer Treat Rep 1985, 69:149-151.
16. Moseley P.L., Hemken C., Hunninghake G.W. Augmentation of fibroblast proliferation by bleomycin. J Clin Invest 1986, 78:1150-1154.
17. Adamson I.Y. Pulmonary toxicity of bleomycin. Environ Health Perspect 1976, 16:119-125.
18. Yoshikawa A., Saura R., Matsubara T., Mizuno K. A mechanism of cisplatin, action: antineoplastic effect through inhibition of neovascularization. Kobe J Med Sci 1997, 43:109-120.
19. Stoter G., Koopman A., Vendrik C.J.P., et al. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol 1989, 7:1099-1104.
20. Meinardi M.T., Gietema J.A., van Veldhuisen D.J., van der Graaf W.T., de Vries E.G., Sleijfer D.T. Long-term chemotherapy related cardiovascular morbidity. Cancer Treat Rev 2000, 26:429-447.
21. Kohn S., Fradis M., Podoshin L., Ben-David J., Zidan J., Robinson E. Endothelial injury of capillaries in the stria vascularis of guinea pigs treated with cisplatin and gentamicin. Ultrastruct Pathol 1997, 21:289-299.
22. Kohn S., Fradis M., Ben-David J., Zidan J., Robinson E. Nephrotoxicity of combined treatment with cisplatin and gentamicin in the guinea pig: glomerular injury findings. Ultrastruct Pathol 2002, 26:371-382.
23. Kirchmair R., Walter D.H., Ii M., et al. Antiangiogenesis mediates cisplatin induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth. Circulation 2005, 111:2662-2670.
24. Minghua Yu, Jianqun Han, Peilin Cui, Min Dai, Hongwei Li, Jian Zhang, et al. Cisplatin up-regulates ICAM-1 expression in endothelial cell via a NF-κB dependent pathway. Cancer Sci 2008, 99(1):391-397.
25. Luke D.R., Vadiei K., Lopez-Berestein G. Role of vascular congestion in cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 1992, 7:1-7.
26. Winston J.A., Safirstein R. Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am J Physiol 1985, 249:F490-F496.
27. Icli F., Karaoguz H., Dincol D., et al. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer 1993, 72:587-593.
28. Nuver J., De Haas E.C., Van Zweeden M., Gietema J.A., Meijer C. Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep 2010, 23:247-253.
29. Nuver J., Smit A.J., Sleijfer D.T., van Gessel Al, van Roon A.M., van der Meer J., et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004, 40:701-706.
30. Nuver J., Smit A.J., van der Meer J., van de Berg M.P., van der Graaf W.T.A., Meinardi M.T., et al. Acute chemotherapy-induced cardiovacular changes in patients with testicular cancer. J Clin Oncol 2005, 23:9130-9137.
31. Lorenz M.W., Markus H.S., Bots M.L., Rosvall M., Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007, 115:459-467.
32. Vaughn D.J., Palmer S.C., Carver J.R., Jacobs L.A., Mohler E.R. Cardiovascular risk in long-term survivors of testicular cancer. Cancer 2008, 112:1949-1953.
33. De Vos F.Y., Nuver J., Willemse P.H., van der Zee A.G., Messeschmidt J., Burgerhof J.G., et al. Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy; cardiovascular risk factors and signs of vascular damage. Eur J Cancer 2004, 40:696-700.
34. Lechner D., Kollars M., Gleiss A., Kyrle P.A., Weltermann A. Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity. J Thromb Haemost 2007, 5:2445-2452.
35. Ito H., Okafuji T., Suzuki T. Vitamin E prevents endothelial injury associated with cisplatin injection into the superior mesenteric artery of rats. Heart Vessels 1995, 10:178-184.
36. Ropper Allan H., Isner Jeffrey M., Losordo Douglas W., et al. Therapy without augmenting tumor growth attenuation or reversal by local vascular endothelial growth factor gene antiangiogenesis mediates cisplatin-induced peripheral neuropathy. Circulation 2005, 111:2662-2670.
37. Togna G.I., Togna A.R., Franconi M., et al. Cisplatin triggers platelet activation. Thromb Res 2000, 99:503-509.
38. Sodhi A., Pai K. Increased production of interleukin-1 and tumor necrosis factor by human monocytes treated in vitro with cisplatin or other biological response modifiers. Immunol Lett 1992, 34:183-188.
39. Gan X.H., Jewett A., Bonavida B. Activation of human peripheralblood- derived monocytes by cis-diamminedichloroplatinum: enhanced tumoricidal activity and secretion of tumor necrosis factor-alpha. Nat Immun 1992, 11:144-155.
40. Stoter G., Koopman A., Vendrik C.J.P., et al. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol 1989, 7:1099-1104.
41. Daher I.N., Yeh E.T. Vascular complications of selected cancer therapies. Nat Clin Pract Cardiovasc Med 2008, 5:797-805.
42. Meinardi M.T., Gietema J.A., van der Graaf W.T., et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000, 18:1725-1732.
43. Bokemeyer C., Berger C.C., Kuczyk M.A., Schmoll H.J. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996, 14:2923-2932.
44. Piketty A.C., Fléchon A., Laplanche A., et al. The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area. Br J Cancer 2005, 93(8):909-914.
45. Morlesse J.F., Jeswani T., Beal I., Wylie P., Bell J. Acute ventricular and aortic thrombosis post chemotherapy. Br J Radiol 2007, 80:e75-e77.
46. Bernard P., Cellarier G., Cremades S., Gisserot O., De Jaureguiberry J.P. Early myocardial infraction associated with chemotherapy for testicular cancer. Rev Med Interne 2006, 27:497-498.
47. Fukunaga T., Soejima H., Sugamura K., Kojima S., Sugiyama S., Sakamoto T., et al. Acute myocardial infarction induced by cisplatin-based combination chemotherapy for malignant melanoma: a case report. J Cardiol 2006, 47:191-195.
48. Mano M.S., Guimaraes J.L., Sutmoller S.F., Reitz A.B., Sutmoller C.S., Di Leo A. Extensive deep vein thrombosis as a complication of testicular cancer treated with the BEP protocol (bleomycin, etoposide and cisplatin): case report. Sao Paulo Med J 2006, 124(1):343-345.
49. Dietrich J., Marienhagen J., Schalke B., Bogdahn U., Schlachetzki F. Vascular neurotoxicity following chemotherapy with cisplatin, ifosfamide and etoposide. Ann Pharmacother 2004, 38:242-246.
50. Weijl N.I., Rutten M.F., Zwinderman A.H., Keizer H.J., Nooy M.A., Rosendaal F.R., et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol 2000, 18:2169-2178.
51. Ohashi S., Yazumi S., Nishio A., Fukui T., Asada M., Chiba T. Acute cerebral infraction during combination chemotherapy with s-1 and cisplatin for a young patient with a mucin-producing adenocarcinoma of the stomach. Intern Med 2006, 45:1049-1053.
52. Ozben B., Kurt R., Oflaz H., Sezer M., Basaran M., Goren T., et al. Acute anterior myocardial infarction after chemotherapy for testicular seminoma in a young patient. Clin Appl Thromb Hemost 2007, 13:439-442.
53. Czaykowski P.M., Moore M.J., Tannock I.F. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol 1998, 160:2021-2024.
54. Starling N., Rao S., Cunningham D., Iveson T., Nicolson M., Coxon F., et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the national cancer research institute upper gastrointestinal clinical studies group. J Clin Oncol 2009, 27:3786-3793.
55. Dieckmann Klaus.-Peter., Gehrckens Ralf. Thrombosis of abdominal aorta during cisplatin-based chemotherapy of testicular seminoma - a case report. BMC Cancer 2009, 9:459.
56. Numico G., Garrone O., Dongiovanni V., Silvestris N., Colantonio I., Di Costanzo G., et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 2005, 103:994-999.
57. de Vosa F.Y.F.L., Nuvera J., Willemsea P.H.B., van der Zeeb A.G.J., Messerschmidtc J., Burgerhofd J.G.M., et al. Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy: cardiovascular risk factors and signs of vascular damage. Eur J Cancer 2004, 40:696-700.
58. Hillege H.L., Fidler V., Diercks G.F., et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002, 106:1777-1782.
59. Strumberg D., Brügge S., Korn M.W., Koeppen S., Ranft J., Scheiber G., et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 2002, 13:229-236.
60. Colleoni M., Rocca A., Sandri M.T., Zorzino L., Masci G., Nolè F., et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002, 13:73-80.
61. Segura A., Yuste A., Cercos A., López-Tendero P., Gironés R., Pérez-Fidalgo J.A., et al. Pulmonary fibrosis induced by cyclophosphamide. Ann Pharmacother 2001, 35:894-897.
62. Kachel D.L., Martin W.J. Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury. J Pharmacol Exp Ther 1994, 268:42-46.
63. Musiatowicz B., Terlikowski S., Sulik M., Famulski W., Giedrojć J., Jakubowski A., et al. Cyclophosphamide-induced changes of serum angiotensin converting enzyme activity and pulmonary microvessels ultrastructure. Rocz Akad Med Bialymst 1997, 42(Suppl 2):88-94.
64. Lipshultz S.E., Colan S.D., Gelber R.D., et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991, 324:808-815.
65. Bristow M.R., Billingham M.E., Mason J.W., et al. Clinical spectrum of anthracycline cardiotoxicity. Cancer Treat Rep 1978, 62:873-879.
66. Taga I., Yamamoto K., Kawai H., Kawabata H., Masada K., Tsuyuguchi Y. The effects of intra-arterially injected adriamycin on microvascular anastomosis. J Reconstr Microsurg 1987, 3:153-158.
67. Kotamraju S., Koronev E.A., Joseph J., Kalyanaraman B. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J Biol Chem 2000, 275:33585-33592.
68. Kalivendi S.V., Kotamraju S., Zhao H., Joseph J., Kalyanaraman B. Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase. Effect of antiapoptotic antioxidants and calcium. J Biol Chem 2001, 276:47266-47276.
69. Sawer D.B., Fukazawa R., Arstall M.A., Kelly R.A. Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res 1999, 84:257-265.
70. Vasquez-Vivar J., Martasek P., Hogg N., Masters B.S., Pritchard K.A., Kalyanaraman B. Endothelial nitric oxide synthase dependent superoxide generation from adriamycin. Biochemistry 1997, 36:11293-11297.
71. Wu S., Ko Y., Teng M., et al. Adriamycin induced cardiomyocyte and endothelial cell apoptosis: In vitro and in vivo studies. J Mol Cell Cardiol 2002, 34:1595-1607.
72. Kaye D.M., Jennings G., Angus J.A. Evidence for impaired endothelium dependent vasodilation in experimental left ventricular dysfunction. Clin Exp Pharmacol Physiol 1994, 21:701-719.
73. Durand E., Scoazec A., Lafont A., et al. In vivo induction of endothelial apoptosis leads to vessel thrombosis and endothelial denudation. Circulation 2004, 109:2503-2506.
74. Asai K., Kudej R.K., Shen Y., et al. Peripheral vascular endothelial dysfunction and apoptosis in old monkeys. Arterioscler Thromb Vasc Biol 2000, 20:1493-1499.
75. Murata T., Yamawaki H., Yoshimoto R., Hori M., Sato K., Ozaki H., et al. Chronic effect of doxorubicin on vascular endothelium assessed by organ culture study. Life Sci. 2001, 69:2685-2695.
76. Ito M., Oguri M., Nasure A., Ito H., Suzuki Y., Satake N. Impaired endothelium-derived relaxation in isolated thoracic aorta of rats with daunomycin-induced nephrosis. J Pharm Exp Ther 1991, 258:388-395.
77. Ulu N., Buikema H., van Gilst W.H., Navis G. Vascular dysfunction in adriamycin nephrosis: different effects of adriamycin exposure and nephrosis. Nephrol Dial Transplant 2008, 23:1854-1860.
78. Singal P.K., Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998, 339:900-905.
79. Shapiro C.L., Hardenbergh P.H., Gelman R., et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 1998, 16:3493-3501.
80. Duquaine D., Hirsch G.A., Chakrabarti A., Han Z., Kehrer C., Brook R., et al. Rapid-onset endothelial dysfunction with adriamycin: evidence for adysfunctional nitric oxide synthase. Vasc Med 2003, 8:101-107.
81. Chow A.Y., Chin C., Dahl G. Rosenthal DNAnthracyclines cause endothelial injury in pediatric cancer patients: a pilot study. J Clin Oncol 2006, 24:925-928.
82. Dengel D.R., Ness K.K., Glasser S.P., Williamson E.B., Baker K.S., Gurney J.G. Endothelial function in young adult survivors of childhood acute lymphoblastic leukaemia. J Pediatr Hematol Oncol 2008, 30:20-25.
83. Mabeta P., Pepper M.S. A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agents. Angiogenesis 2009, 12(1):81-90.
84. Adamson I.Y. Pulmonary toxicity of bleomycin. Environ Health Perspect 1976, 16:119-125.
85. Vogelzang N.J., Bosl G.J., Johnson K., Kennedy B.J. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Int Med 1981, 95:288-292.
86. Singh S., De Trafford J.C., Baskerville P.A., Martin J.F. Response of digital arteries to endothelium dependent and independent vasodilators in patients with Raynaud's phenomenon. Eur J Clin Invest 1995, 25(3):182-185.
87. Berger C.C., Bokemeyer C., Schneider M., Kuczyk M.A., Schmoll H.J. Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 1995, 31A(13-14):2229-2238.
88. Toumbis-Ioannou E., Cohen P.R. Chemotherapy-induced Raynaud's phenomenon. Cleve Clin J Med 1994, 61(3):195-199.
89. Fossa S.D., Lehne G., Heimdal K., Theodorsen L. Clinical and biochemicallong-term toxicity after postoperative cisplatin-based chemotherapy in patients with low-stage testicular cancer. Oncology 1995, 52(4):300-305.
90. Adamson I.Y.R., Bowden D.H. The pathogenesis of bloemycin induced pulmonary fibrosis in mice. Am J Pathol 1974, 77:185-191.
91. Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001, 120(2):617-624. [Review].
92. Aso Y., Yoneda K., Kikkawa Y. Morphologic and biochemical study of pulmonary changes induced by bleomycin in mice. Lab Invest 1976, 35(6):558-568.
93. Catravas J.D., Lazo J.S., Dobuler K.J., Mills L.R., Gillis C.N. Pulmonary endothelial dysfunction in the presence or absence of interstitial injury induced by intratracheally injected bleomycin in rabbits. Am Rev Respir Dis 1983, 128(4):740-746.
94. Hoyt D.G., Rizzo M., Gerritsen M.E., Pitt B.R., Lazo J.S. Integrin activation protects pulmonary endothelial cells from the genotoxic effects of bleomycin. Am J Physiol 1997, 273(3 Pt 1):L612-L617.
95. Dirix L.Y., Libura M., Vermeulen Libura.J., PB De., Bruijn E.A., Van Oosterom A.T. In vitro toxicity studies with mitomycins and bleomycin on endothelial cells. Anticancer Drugs 1997, 8:859-886.
96. Adamson I.Y., Orr F.W., Young L. Effects of injury and repair of the pulmonary endothelium on lung metastasis after bleomycin. J Pathol 1986 Dec, 150(4):279-287.
97. Sato N., Suzuki Y., Nishio K., Suzuki K., Naoki K., Takeshita K., et al. Roles of ICAM-1 for abnormal leukocyte recruitment in the microcirculation of bleomycin-induced fibrotic lung injury. Am J Respir Crit Care Med 2000, 161(5):1681-1688.
98. Phan S.H., Gharee-Kermani M., Wolber F., Ryan U.S. Bleomycin stimulates production of transforming growth factor-beta by rat pulmonary artery endothelial cells. Chest 1991, 99:S66.
99. Sleijfer S., Vujaskovic Z., Limburg P.C., Schraffordt Koops H., Mulder N.H. Induction of tumor necrosis factor-alpha as a cause of bleomycin-related toxicity. Cancer 1998, 82(5):970-974.
100. Azuma A., Takahashi S., Nose M., Araki K., Araki M., Takahashi T., et al. Role of E-selectin in bleomycin induced lung fibrosis in mice. Thorax 2000, 55(2):147-152.
101. Fichtner F., Koslowski R., Augstein A., Hempel U., Röhlecke C., Kasper M. Bleomycin induces IL-8 and ICAM-1 expression in microvascular pulmonary endothelial cells. Exp Toxicol Pathol 2004, 55(6):497-503.
102. Ishii H., Takada K. Bleomycin induces E-selectin expression in cultured umbilical vein endothelial cells by increasing its mRNA levels through activation of NF-kappaB/Rel. Toxicol Appl Pharmacol 2002, 184(2):88-97.
103. Miyamoto H., Sugawara I., Azuma A., Saito Y., Kohno N., Kudoh S. Differential secretion of cytokines and adhesion molecules by HUVEC stimulated with low concentrations of bleomycin. Cell Immunol 2002, 219(2):73-81.
104. Rosso A., Mitchell J.B., McPherson S., Friedman N. Alteration of bleomycin cytotoxicity by glutathione depletion or elevation. Int J Radiat Oncol Biol Phys 1984, 10:1675-1678.
105. Galvan L., Huang C.H., Prestayko A.W., Stout J.T., Evans J.E., Crooke S.T. Inhibition of bleomycin-induced DNA breakage by superoxide dismutase. Cancer Res 1981, 41:5103-5106.
106. Giaccia A.J., Lewis A.D., Denko N.C., Cholon A., Evans J.W., Waldren C.A., et al. The hypersensitivity of the Chinese hamster ovary variant BL-10 to bleomycin killing is due to a lack of glutathione S-transferase-α activity. Cancer Res 1991, 51:4463-4469.
107. Shi M.M., Iwamoto T., Forman H.J. Γ-Glutamylcysteine synthetase and GSH increase in quinone-induced oxidative stress in BPAEC. Am J Physiol Lung Cell Mol Physiol 1994, 267:L414-L421.
108. Stefan Sleijfer Bleomycin-Induced Pneumonitis. CHEST 2001, 120:617-624.
109. Crawley D.E., McCormack D.G., Evans T.W. Bleomycin-induced acute lung injury in the rat does not influence pulmonary vascular responsiveness in vitro. Crit Care Med 1992, 20(5):641-644.
110. Gong F., Tang H., Lin Y., Gu W., Wang W., Kang M. Gene transfer of vascular endothelial growth factor reduces bleomycin-induced pulmonary hypertension in immature rabbits. Pediatr Int 2005, 47(3):242-247.
111. Yoshimura S., Nishimura Y., Nishiuma T., Yamashita T., Kobayashi K., Yokoyama M. Overexpression of nitric oxide synthase by the endothelium attenuates bleomycin-induced lung fibrosis and impairs MMP-9/TIMP-1 balance. Respirology 2006, 11(5):546-556.
112. Czauderna P., Katski K., Kowalczyk J., Kurylak A., Lopatka B., Skotnicka-Klonowicz G., et al. Venoocclusive liver disease (VOD) as a complication of Wilms' tumour management in the series of consecutive 206 patients. Eur J Pediatr Surg 2000, 10(5):300-303.
113. Clarke C.S., Otridge B.W., Carney D.N. Thromboembolism. A complication of weekly chemotherapy in the treatment of non-Hodgkin's lymphoma. Cancer 1990, 66:2027-2030.
114. Dexeus F., Logothetis C.J., Samuels M.L., Hossan E., von Eschenbach A.C. Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer. Cancer Treat Rep 1985, 69:885-886.
115. Doll D.C., List A.F., Greco F.A., Hainsworth J.D., Hande K.R., Johnson D.H. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ cell tumors of the testis. Ann Int Med 1986, 105:48-51.
116. Lejonc J.L., Vernant J.P., Macquin J., Castaigne A. Myocardial infarction following vinblastine treatment. Lancet 1980, 2:692.
117. Vogelzang N.J., Bosl G.J., Johnson K., Kennedy B.J. Raynaud's phenomenon: a common toxicity after combination chemotherapy or testicular cancer. Ann Int Med 1981, 95:288-292.
118. Subar M., Muggia F.M. Apparent myocardial ischemia associated with vinblastine administration. Cancer Treat Rep 1986, 70:690-691.
119. Samuels B.L., Vogelzang N.J., Kennedy B.J. Severe vascular toxicity associated with vinblastine, bleomycin and cisplatin chemotherapy. Cancer Chemother Pharmacol 1987, 19:253-256.
120. Mikaelian I., Buness A., de Vera-Mudry M.C., Kanwal C., Coluccio D., Rasmussen E., et al. Primary endothelial damage is the mechanism of cardiotoxicity of tubulin-binding drugs. Toxicol Sci 2010, 117(1):144-151. [Epub 2010 Jul 12].
121. Stoter G., Koopman A., Vendrik C.J.P., et al. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol 1989, 7:1099-1104.
122. Williams S.D., Birch R., Einhorn L.H., Irwin L., Greco F.A., Loehrer P.J. Treatment of dissiminated germ-cell tumors with cisplatin, bleomycine and either vinblastine or etoposide. N Engl J Med 1987, 316:1435-1440.
123. Cwikiel M., Zhang B., Eskilsson J., Wieslander J.B., Albertsson M. The influence of 5-fluorouracil on the endothelium in small arteries. An electron microscopic study in rabbits. Scanning Microsc 1995, 9(2):561-576.
124. Kinhult S., Albertsson M., Eskilsson J., Cwikiel M. Antithrombotic treatment in protection against thrombogenic effects of 5-fluorouracil on vascular endothelium: a scanning microscopy evaluation. Scanning 2001, 23(1):1-8.
125. Basaki Y., Chikahisa L., Aoyagi K., et al. Gamma-hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. Angiogenesis 2001, 4:163-173.
126. Cwikiel M., Eskilsson J., Albertsson M., Stavenow L. The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells culture. Ann Oncol 1996, 7:731-737.
127. Mosseri M., Fingert H.J., Varticovski L., Chokshi S., Isner J.M. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res 1993, 53(13):3028-3033.
128. Sclafani F., Carnaghi C., Colombo P., Bozzarelli S., De Vincenzo F., Rimassa L., et al. Case report of acute aortic dissection during treatment with capecitabine for a late recurrence of breast cancer. Chemotherapy 2010, 56(3):203-207.
129. Allerton R. Acute mesenteric ischaemia associated with 5-FU, cisplatin and vincristine chemotherapy. Clin Oncol (R Coll Radiol) 1996, 8(2):116-117.
130. Mertsch K., Grune T., Kunstmann S., et al. Protective effects of the thiophosphate amifostine (WR2721) and a lazaroid (U83836E) on lipid peroxidation in endothelial cells during hypoxia/reoxygenation. Biochem Pharmacol 1998, 56:945-954.
131. Capizzi R.L., Oster W. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials. Int J Hematol 2000, 72:425-435.
132. Steward W.P., Thomas A.L., Morgan B., et al. Extended phase I study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK222584 in combination with oxaliplatin/5-fluorouracil (5-FU)/leucovorin as first line treatment for metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003, 22:274.
133. Giannopoulou E., Katsoris P., Kardamakis D., Papdimitriou E. Amifostine inhibits angiogenesis in vivo. J Pharmacol Exp Ther 2003, 304:729-737.
134. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23):2335-2342.
135. Alter P., Herzum M., Soufi M., Schaefer J.R., Maisch B. Cardiotoxicity of 5-fluorouracil. Cardiovasc Hematol Agents Med Chem 2006, 4(1):1-5.
136. Anderson R.N., Lokich J.J., Moore C. The syndrome of 5-fluorouracil cardiotoxicity: an elusive cardiopathy. Cancer 1993, 72:2287-2288.
137. Grandi A.M., Pinotti G., Morandi E., et al. Non-invasive evaluation of cardiotoxicity of 5-fluorouracil and low doses of folinic acid: a one-year follow-up study. Ann Oncol 1997, 8:705-708.
138. Sudhoff T., Enderle M.D., Pahlke M., Petz C., Teschendorf C., Graeven U., et al. 5-Fluorouracil induces arterial vasoconstrictions. Ann Oncol 2004, 15(4):661-664.
139. Tsibiribi P., Bui-Xuan C., Bui-Xuan B., Lombard-Bohas C., Duperret S., Belkhiria M., et al. Cardiac lesions induced by 5-fluorouracil in the rabbit. Hum Exp Toxicol 2006 Jun, 25(6):305-309.
140. Merkle C.J., Moore I.M., Penton B.S., Torres B.J., Cueny R.K., Schaeffer R.C., et al. Methotrexate causes apoptosis in postmitotic endothelial cells. Biol Res Nurs 2000, 2(1):5-14.
141. Zeng L., Yan Z., Ding S., Xu K., Wang L. Endothelial injury, an intriguing effect of methotrexate and cyclophosphamide during hematopoietic stem cell transplantation in mice. Transplant Proc 2008, 40(8):2670-2673.
142. Fuskevag O.M., Kristiansen C., Olsen R., Aarbakke J., Lindsal S. Icrovascular perturbations in rats receiving the maximum olerated dose of methotrexate or its metabolite 7-hydroxymethotrexate. Ultrastruct Pathol 2000, 24:325-332.
143. Hoekstra M., Haagsma C.J., Doelman C.J., van de Laar M.A. Intermittent rises in plasma homocysteine in patients with rheumatoid arthritis treated with higher dose methotrexate. Ann Rheum Dis 2005, 64(1):141-143.
144. Hornung N., Ellingsen T., Stengaard-Pedersen K., Poulsen J.H. Folate, homocysteine, and cobalamin status in patients with rheumatoid arthritis treated with methotrexate, and the effect of low dose folic acid supplement. J Rheumatol 2004, 31(12):2374-2381.
145. Woo K.S., Chook P., Lolin Y.I., Cheung A.S., Chan L.T., Sun Y.Y., et al. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997, 96(8):2542-2544.
146. Verweij J., Clavel M., Chevalier B. Paclitaxel (Taxol) and, docetaxel (Taxotere): not simply two of a kind. Ann Oncol 1994, 5:495-505.
147. Schwartz E.L. Antivascular actions of microtubule-binding drugs. Clin Cancer Res 2009, 15(8):2594-2601.
148. Wood S.C., Tang X., Tesfamariam B. Paclitaxel potentiates inflammatory cytokine-induced prothrombotic molecules in endothelial cells. J Cardiovasc Pharmacol 2010, 55(3):276-285.
149. Hotchkiss K., Ashton A., Mahmood R., et al. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (taxotere): association with impaired repositioning of the Microtubule Organizing Center 1. Mol Cancer Ther 2002, 1(13):1191-1200.
150. Vacca A., Ribatti D., Iurlaro M., et al. Docetaxel versus paclitaxel for antiangiogenesis. J Hematother Stem Cell Res 2002, 11(1):103-118.
151. Verweij J., Clavel M., Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 1994, 5:495-505.
152. Behar A., Pujade-Lauraine E., Maurel A., et al. The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. Br J Clin Pharmacol 1997, 43:653-658.
153. Semb K.A., Aamdal S., Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 1998, 16:3426-3432.
154. Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O'Shaughnessy C., Mann J.T., et al. TAXUS-IV Investigators. One year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004, 109:1942-1947.
155. Joner M., Finn A.V., Farb A., Mont E.K., Kolodgie F.D., Ladich E., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006, 48:193-202.
156. Farb A., Heller P.F., Shroff S., Chenq L., Kolodgie F.D., Carter A.J., et al. Pathological analysis of local delivery of paclitaxel via apolymer-coated stent. Circulation 2001, 104(4):473-479.
157. Togni M., Raber L., Cocchia R., Wenaweser P., Cook S., Windecker S., et al. Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. Int J Cardiol 2007, 120(2):212-220.
158. Shin D.I., Kim P.J., Seung K.B., Kim D.B., Kim M.J., Chang K., et al. Drug-eluting stent implantation could be associated with long-term coronary endothelial dysfunction. Int Heart J 2007, 48(5):553-567.
159. Naumova E., Ubezio P., Garofalo A., et al. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Clin Cancer Res 2006, 12(6):1839-1849.
160. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357(26):2666-2676.
161. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550.
162. Strijbos M.H., Gratama J.W., Schmitz P.I., et al. Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel. Eur J Cancer 2010, 46(11):2027-2035.
163. Shaked Y., Henke E., Roodhart J.M., et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008, 14(3):263-273.
164. Raitakari O.T., Celermajer D.S. Flow-mediated dilatation. Br J Clin Pharmacol 2000, 50(5):397-404.
165. Henderson A. Endothelial dysfunction: a reversible clinical measure of atherogenic susceptibility and cardiovascular inefficiency. Int J Cardiol 1997, 62(Suppl. 1):S43-S48.
166. Drexler H., Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol 1999, 31(1):51-60.
167. Widlansky M.E., Gokce N., Keaney J.F., Vita J.A. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003, 42(7):1149-1160.